PARP GENOMIC VARIANTS CONFERRING RESISTANCE AND SENSITIZATION TO CHEMOTHERAPY UNDER INHIBITION

摘要

A method is provided for selecting a subject diagnosed with cancer as a candidate for treatment with a PARP1 inhibitor, or both a PARP1 inhibitor and a chemotherapeutic agent such as an alkylating agent. The method includes detecting the presence or absence of a mutation in a non- coding region of a PARP1 gene, wherein the presence of a mutation in the PARP1 gene indicates that the cancer can be treated with the PARP1 inhibitor, optionally in conjunction with the chemotherapeutic agent. In a specific, non-limiting example, the PARP1 inhibitor is verliparib (ABT-888).